| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YEBEH.2007.07.010 |
| P698 | PubMed publication ID | 17936687 |
| P2093 | author name string | Elizabeth A Thiele | |
| David A Muzykewicz | |||
| Elkan F Halpern | |||
| Peter Newberry | |||
| Nicole Danforth | |||
| P2860 | cites work | Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs | Q24535643 |
| Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. | Q24540242 | ||
| Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34 | Q28245141 | ||
| Molecular Genetic and Phenotypic Analysis Reveals Differences between TSC1 and TSC2 Associated Familial and Sporadic Tuberous Sclerosis | Q28251056 | ||
| Identification and characterization of the tuberous sclerosis gene on chromosome 16 | Q28257738 | ||
| Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables | Q31402130 | ||
| Children of school age: the influence of antiepileptic drugs on behavior and intellect | Q34164907 | ||
| Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children | Q34167725 | ||
| Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. | Q34531886 | ||
| Subependymal giant cell tumors in tuberous sclerosis complex | Q34552158 | ||
| Diagnosis of tuberous sclerosis complex | Q34552831 | ||
| Psychotropic effects of antiepileptic drugs | Q34589572 | ||
| Neuropsychiatric problems in tuberous sclerosis complex | Q35783807 | ||
| The psychiatric comorbidity of epilepsy. | Q35881923 | ||
| Behavioral and cognitive aspects of tuberous sclerosis complex | Q35962456 | ||
| Infantile spasms and intellectual outcomes in children with tuberous sclerosis complex | Q36207150 | ||
| Psychiatric disorders in candidates for surgery for epilepsy. | Q36894514 | ||
| Psychopathology in tuberous sclerosis: an overview and findings in a population-based sample of adults with tuberous sclerosis. | Q40303846 | ||
| Attention deficit disorder: a review of the past 10 years | Q41074795 | ||
| A Double-blind, Placebo-Controlled Study of Risperidone in Adults With Autistic Disorder and Other Pervasive Developmental Disorders | Q42540933 | ||
| Genotype and psychological phenotype in tuberous sclerosis | Q43073866 | ||
| Mania in a five-year-old child with tuberous sclerosis | Q44700523 | ||
| Citalopram as treatment of depression in patients with epilepsy | Q44931470 | ||
| Poor mental development in patients with tuberous sclerosis complex: clinical risk factors | Q48499881 | ||
| Anorexia nervosa in a child with tuberous sclerosis complex | Q48843596 | ||
| Development, behaviour and seizures in 300 cases of tuberous sclerosis | Q48875347 | ||
| Autistic behaviour and attention deficits in tuberous sclerosis: a population-based study | Q50304648 | ||
| Neuropsychiatric aspects of tuberous sclerosis | Q50306376 | ||
| Cognitive and behavioral correlates of tuberous sclerosis complex | Q50306912 | ||
| Psychiatric disorder among children with tuberous sclerosis | Q50308353 | ||
| A multicenter study on the prevalence of psychiatric disorders among new referrals for epilepsy in Japan | Q51950614 | ||
| Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States | Q51994229 | ||
| Psychiatric manifestations of tuberous sclerosis | Q52016695 | ||
| Case study: risperidone treatment of children and adolescents with developmental disorders | Q52199262 | ||
| Autism and tuberous sclerosis | Q67556845 | ||
| The development of psychiatric disorder among schoolchildren with epilepsy | Q70466294 | ||
| Treatment of Interictal Depression with Citalopram in Patients with Epilepsy | Q73370735 | ||
| Psychological profile of adults with tuberous sclerosis complex | Q80057109 | ||
| P433 | issue | 4 | |
| P921 | main subject | tuberous sclerosis | Q1362721 |
| P304 | page(s) | 506-513 | |
| P577 | publication date | 2007-10-23 | |
| P1433 | published in | Epilepsy Behavior | Q15746410 |
| P1476 | title | Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex | |
| P478 | volume | 11 |
| Q57168896 | A clinical update on tuberous sclerosis complex-associated neuropsychiatric disorders (TAND) |
| Q92819914 | A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC) |
| Q34541036 | Adult ADHD and Comorbid Somatic Disease: A Systematic Literature Review |
| Q37803579 | Advances in understanding behavioral phenotypes in neurogenetic syndromes |
| Q34770323 | Assessing children with ADHD in primary care settings |
| Q33664831 | Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus |
| Q37608840 | Attention-deficit hyperactivity disorder (ADHD) and tuberous sclerosis complex |
| Q35937927 | Atypical presentation of tuberous sclerosis and obsessive compulsive disorder in an adult male. |
| Q36344050 | Autism spectrum disorder in tuberous sclerosis complex: searching for risk markers |
| Q36101188 | Autism spectrum disorders: from genes to neurobiology |
| Q53058748 | Autism traits in children and adolescents with Cornelia de Lange syndrome |
| Q34494739 | Autworks: a cross-disease network biology application for Autism and related disorders |
| Q50309438 | Behavior problems in children with tuberous sclerosis complex and parental stress |
| Q44894135 | Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of Tuberous Sclerosis Complex |
| Q43154847 | Bipolar disorder and tuberous sclerosis complex: is it a mere coincidence? |
| Q36818268 | Brain MR spectroscopic abnormalities in “MRI-negative” tuberous sclerosis complex patients |
| Q37892527 | Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review |
| Q36226150 | Characterizing sleep disorders of adults with tuberous sclerosis complex: A questionnaire-based study and review |
| Q42371898 | Clinical Usefulness of Aripiprazole and Lamotrigine in Schizoaffective Presentation of Tuberous Sclerosis |
| Q37958281 | Cognitive and adaptive development of patients with tuberous sclerosis complex: A retrospective, longitudinal investigation |
| Q37833765 | Cognitive-Adaptive Disabilities |
| Q34816124 | Current management of tuberous sclerosis complex |
| Q34633063 | Current options for the treatment of facial angiofibromas |
| Q30529898 | Deletion of Rictor in neural progenitor cells reveals contributions of mTORC2 signaling to tuberous sclerosis complex |
| Q39362117 | Dermatological manifestations of tuberous sclerosis complex (TSC). |
| Q39414530 | Dermatologische Manifestationen der tuberösen Sklerose (TSC). |
| Q91832610 | Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex |
| Q29616013 | Etiological heterogeneity in autism spectrum disorders: More than 100 genetic and genomic disorders and still counting |
| Q53152173 | Facial Angiofibroma Severity Index (FASI): reliability assessment of a new tool developed to measure severity and responsiveness to therapy in tuberous sclerosis-associated facial angiofibroma. |
| Q35044148 | Food allergy and food-based therapies in neurodevelopmental disorders. |
| Q38012951 | From genes to cognition in tuberous sclerosis: Implications for mTOR inhibitor-based treatment approaches |
| Q33750454 | From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis |
| Q36231691 | Graded loss of tuberin in an allelic series of brain models of TSC correlates with survival, and biochemical, histological and behavioral features |
| Q33845794 | Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex. |
| Q35009587 | Increased levels of anxiety-related behaviors in a Tsc2 dominant negative transgenic mouse model of tuberous sclerosis |
| Q30746587 | Mechanism-based treatment in tuberous sclerosis complex |
| Q39405847 | New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND). |
| Q38021859 | Primary care management of tuberous sclerosis complex in children |
| Q36019947 | Rapamycin attenuates aggressive behavior in a rat model of pilocarpine-induced epilepsy |
| Q34024856 | Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders |
| Q37464956 | Resting and task-modulated high-frequency brain rhythms measured by scalp encephalography in infants with tuberous sclerosis complex. |
| Q34808699 | Self-injurious behavior and tuberous sclerosis complex: frequency and possible associations in a population of 257 patients |
| Q58755156 | TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study |
| Q50313740 | The neuroanatomical phenotype of tuberous sclerosis complex: focus on radial migration lines |
| Q41990498 | Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up |
| Q59330605 | Tuberous Sclerosis Complex: Clinical Spectrum and Epilepsy: A Retrospective Chart Review Study |
| Q35593184 | Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist |
| Q38994919 | Tuberous sclerosis complex: From molecular biology to novel therapeutic approaches. |
| Q59298217 | Tuberöse Sklerose im Kindes- und Jugendalter |
| Q54978861 | mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model. |
Search more.